Modality
Nanobody
MOA
JAK1i
Target
BCMA
Pathway
Fibrosis
IPFGAThymoma
Development Pipeline
Preclinical
Dec 2021
→ Dec 2030
PreclinicalCurrent
NCT04375176
1,387 pts·IPF
2021-12→2030-12·Not yet recruiting
1,387 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-264.7y awayInterim· IPF
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Not yet…
Catalysts
Interim
2030-12-26 · 4.7y away
IPF
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04375176 | Preclinical | IPF | Not yet recr... | 1387 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |